Comparison of the fifth batch of volume purchases with the first four batches: variety, enterprise, degree of competition...

On May 10th, the fifth batch of national procurement (hereinafter referred to as "this batch") began to declare information.

Variety: the most in number, injections play the leading role

There are 60 varieties, 202 specifications, and 30 injections in this batch, which are the most since the previous national procurement.

There were only 3, 1, 3, and 8 injections in the first four batches, and the number of injections this time was nearly twice the sum of the previous four batches.

According to data from Minai.

2

Treatment area: Digestion/metabolism and anti-infective drugs are still the mainstream

This batch of varieties involved the most in the field of treatment are 12 digestion/metabolism, 11 anti-infection and 10 anti-tumor/immunomodulators.

3

Competition level: slowing down

Up to now, the number of companies that have passed the consistency evaluation of this batch of varieties are mostly concentrated in 2 (20 varieties), 3 (19 varieties) and 4 (10 varieties).

4

Enterprises: China Biotech, Yangtze River, Qilu, and Kelun still have the most

The largest number of varieties involved in this batch is China Biopharmaceuticals (13 varieties).

At the executive meeting of the State Council held on January 15th, the Premier requested that “centralized procurement should reduce the burden on patients while taking into account the reasonable profits of the enterprise” and “work hard to make this reform benefit patients, enterprises, and medical institutions.

The lowest bid price is no longer less than one dime.